Arctoris Ltd is an Oxford-based startup revolutionising cancer research by combining robotics & AI. Arctoris enables researchers to configure their experiments remotely and have them executed in a fully automated cloud laboratory.
Ares Genetics is revolutionizing infectious disease diagnostics and therapeutics by artificial intelligence based DNA testing to improve patient outcomes at reduced costs. Our Vision: Conquering emerging antibiotic resistance, one of the biggest 21st century health threats and improving outcomes for patients with severe infections. Our Mission: Revolutionizing infectious disease diagnostics and therapeutics by translating success stories from next-generation diagnostics and precision medicine to microbial infections.
Bacteriobator was co-founded as an Accelerator by scientists from the Max-Planck-Institutes in Martinsried with the objective to identify, develop and invest in the most promising medical antimicrobial technologies in Europe. Our general USP include IP, a high technology readiness level, good synergies within the Accelerator and the technology clusters. A clear commercial perspective in attractive B2B markets and no high-risk long term developments. Examples include diagnostics, active components and materials. Strong pipeline, also for the coming years.
BRAINCURES is a biology-powered platform company with a unique in silico approach to de-risk and accelerate drug discovery and biomarker-based clinical decision making for brain diseases. Their biology-powered Discovery Engine can be exploited to turn data on compounds, diseases, drugs, patients and pipelines into opportunities for precision medicine without data-training associated with artificial intelligence (AI) approaches. Other applications include Companion Diagnostics, Biomarkers and Novel Treatment identification.
Climedo accelerates the introduction of personalised therapies by providing an intelligent platform for digitally connected medical research. Climedo is unique in that it offers rich functionality for electronic data capture, query management and real-time monitoring. As a result, it demonstrably increases the efficiency, quality and transparency of clinical trials.
EpiBloc develops precision drugs for autoimmune diseases. The company has developed an immune mapping platform allowing researchers to identify epitopes that disease-causing autoantibodies are targeting. The epitope peptides discovered with our platform are then used to selectively eliminate disease-causing autoantibodies. The company will capitalize on its proprietary immune mapping platform Mimotope Variation Analysis (MVA) by developing applications in-house along with finding partners interested in applying MVA to develop diagnostic tests and precision drugs. MVA delivers a high throughput analysis of the antibody repertoire to identify disease-specific antibody profiles via epitope peptides. This was previously difficult due to the vast number of antibodies making it near impossible to account for antibody diversity and understand correlations to specific diseases. We have solved this by combining random display libraries and machine learning algorithms allowing us to capture millions of antibodies and pinpoint their involvement in various diseases.
The biotech-company EraCal Therapeutics Ltd. develops a novel anti-obesity drug (Era-107), which outperforms the current standard of care in efficacy and in safety in zebrafish, mice, and rats. An ambitious team with world-class advisors targets human trials by 2021. A novel drug discovery platform enabled Era-107 identification and is applicable to other indications. EraCal is a spin-off of the University of Zurich and Harvard University and opens its seed round in spring 2019.
Gasgon Medical is an award-winning medical technology startup based in Ireland. They are developing new technology to improve management of fluids in common IV procedures, with a goal of reducing occurrence of Vascular Air Embolism and the associated adverse outcomes for patients and healthcare systems globally.
iConcipio’s digital solution can alleviate the demand on higher education institutions by offering students personalized support to enhance their wellbeing, take care of their mental health, and improve their study skills.
The company was founded in 2011 after winning the King's College London Business Plan Competition Prize and our product, MePlusMe, was shortlisted from over 2,400 other projects worldwide for the Falling Walls Young Innovator of the Year 2016 competition in Berlin. www.iconcipio.com
The ImmunoLogik GmbH develops the innovative lead candidate and DUB inhibitor IML-106 for the efficient and essential treatment of patients with cART resistances, who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate IML-106 targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.
The MUS.I.C. project brings along a real chance for minimally-invasive, functional regeneration of the damaged urinary sphincter muscle by injection of patient`s own cells in combination with physical stimulation of the pelvic floor, thereby offering the solution for treating involuntary loss of urine.
OncoLize BV (2017- the Netherlands) develops injectable drug depots based on generic chemo drugs, now reformulated for local and slow release of the drugs inside solid tumors.
The polymer-drug formulations are injected straight into the tumor with thin, long needles where they form solid depots within seconds, and slowly erode, while gradually releasing their cargo inside the tumor from days to weeks, as designed. Small molecule drugs, peptides and MAb's are release with >95% bioactivity. Autoclavable. The technology platform has been scaled-up and proven extensively in non-clinical settings with the biggest Pharma partners and academic medical centres in other disease indications such as Diabetes, Osteo Arthritis and Tumor Vaccination.OncoLize is a carve-out from the InGell Labs company from Groningen - NL, established and managed by the founders of the InGell® technology, Mike de Leeuw and Leo de Leede.
Next Generation Programmable Therapies Pattern BioSciences is an early stage biotechnology start up company and an ETH Zurich spin-off. The company develops programmable cancer gene therapies using gene circuit technologies.
PlasFree focus on the development of an innovative medical device ClearPlasma™ that modifies human plasma to improve treatment for massive bleeding. ClearPlasma™ effectively and specifically extracts Fibrinolytic proteins that are responsible for dissolving blood clots. By doing so, ClearPlasma™ modifies the human plasma generating improved plasma that is more prone to coagulation. Thus, our product aims to revolutionize the treatment of massive bleeding and to enable safe and effective treatment to massive bleeding around the world.
SeaGull Tx is a biotech company developing a mutated semaphorin 3A (SGL10060) to reprogram the tumour microenvironment for the treatment of solid tumours. By reprogramming the TME using SGL10060, strong inhibition of tumour growth, significant decreases in hypoxia and metastases and pronounced increases in anti-tumoural immune cell populations are seen, showing efficacy as a monotherapy. When used in combination SOC treatments (both chemo and IO), significant enhancement in efficacy and reduction in resistance are seen. The company was created in Strasbourg in 2017 and has seed funding of €1.2m. We are looking for €16m to take the product through to the end of Ph IIa. Production has already been derisked with early process development showing antibody level titres. The company operates using a lean structure, with key experience internally planning and driving outsourced execution.
SiBreaX develops drugs based on targeted drug delivery via silicate nanoparticles. For the first time, SiBreaX nanoparticles allow for the efficient intracellular delivery of proteins, peptides, and RNA, as well as for the specific delivery of drugs to lung tissue – thereby opening access to breakthrough therapeutics. As the first, easily accessible lead drugs, SiBreaX develops improved drugs for respiratory diseases based on targeted delivery to lung tissue thereby reducing side-effects and increasing efficacy. In addition, SiBreaX partners (co-development, joint ventures, licensing) with pharmaceutical companies to develop drugs requiring targeted delivery. Leveraging the full potential of the technology, SiBreaX strives to develop breakthrough drugs based on the routine intracellular delivery of peptides, proteins, and RNA. SiBreaX unique novel drug delivery system is comprised of triggered-breakable silicate nanoparticles. The nanoparticles encapsulate almost any drug type at a high load, deliver drugs within the capsule to distinct tissue, and release the drug at the target site via a site-specific trigger. Fast degradation of SiBreaX particles via the trigger ensures safe use. SiBreaX targeted drug delivery allows for the administration of problematic substances, the reduction of side-effects of drugs by targeted delivery, and facilitates intracellular delivery of drugs. Notably, SiBreaX nanoparticles allow for the efficient intracellular delivery of proteins, peptides, and RNA as well as for the specific delivery of drugs to lung tissue for the first time. Leveraging the technology, SiBreaX opens access to the development of numerous innovative drugs. SiBreaX is a Swiss BioTech company headquartered in Zurich.
SunRegen Healthcare AG is a pioneering biopharmaceutical company based in Basel Area of Switzerland. Our mission is to develop novel drugs for the unmet medical needs, especially for neurological diseases including Optic Atrophy and the neurodegenerative diseases. The co-founder team of SunRegen has solid business and management experience in multinational companies and very strong drug development background. SAB members are from big pharma, and each with over 30 years drug research experience. SunRegen is well recognized by the biotech industry and supported by Innosuisse, BaseLaunch, H2020 SME Instrument programs.
Surge-on Medical is improving minimally invasive surgeries by developing 'freedimensional' instruments to empower surgeons. Its patented cable-free technology makes any instrument steerable, detachable and cleanable. The first product, the Steerable Punch, is an arthroscopic cutter for knee surgery. Additionally, Surge-on Medical is developing a laparoscopy surgery line and a portable surgical robot.
Synendos Therapeutics is a pharmaceutical company founded in 2019 as a spin-off of the University of Bern. Synendos develops a new class of small molecules that modulate the endocannabinoid system with a new mechanism of action by hitting an as-yet unprecedented drug target. These molecules act as selective endocannabinoid reuptake inhibitors (SERIs). The design and development of second generation SERIs started in 2012 from an in silico ligand-polypharmacophore screening of 12M compounds which was followed by an effective medicinal chemistry program (in collaboration with a CRO) that led to the identification of a preclinical drug candidate (2019). SERIs are covered by solid IP protection (four patent families). First-in-man, phase I trial is expected for 2020/21. SERIs are first-in-class inhibitors that represent an innovative therapeutic approach for central nervous system diseases characterized by (endo)cannabinoid deficiency. SERIs are the only modulators that can restore the full spectrum of endocannabinoid activities acting with a self-limiting mechanism of action. This offers the advantage of a safe and effective treatment that enables endogenous polypharmacology by restoring the normal functioning of different neuronal circuits in the brain. Synendos aims to develop a new breakthrough therapy for neuropsychiatric disorders characterized by endocannabinoid deficiency, with a special focus on anxiety and mood-related diseases, in particular post-traumatic stress disorder (PTSD), which has a high unmet medical need. In addition, Synendos envisages to create a promising pipeline by exploiting the exclusive access to the endocannabinoid transport mechanism and developing third generation target-based SERIs with a broad applicability in the area of neuropsychiatric, neurodegenerative and inflammatory diseases. The development of SERIs was supported by a number of non-dilutive grants (NCCR-TransCure, University of Bern, EIN-Roche, Swiss Multiple Sclerosis Society, Innosuisse) and Synendos is currently supported by BaseLaunch (phase II grant) and Venture Kick (stage I grant).
TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016. This was supported by public grants e.g. EXIST and a seed funding by HTGF. We are now looking for a Series A of 18 m € to further develop the portfolio and to get approval for the 1st indication in Tx by 2023. TolerogenixX foresees a potential of > 5 b € of its portfolio. TolerogenixX is managed by an interdisciplinary, highly experienced team.